Riskpilot← Back to searchSign inGet full accessNP Bioinnovation A/S
A/SActiveCVR 41598263Vandtårnsvej 62A, 1. bManufacture of pharmaceutical preparations · NACE 2120Est. 202012 employees
Revenue 2025
DKK -32K
-45% vs 2024
EBITDA margin
101.6%
+44% vs 2024
Equity ratio
84.1%
Financial strength
Net profit 2025
DKK -60K
+25% vs 2024
| Revenue | DKK -32K | -45% |
| EBITDA | DKK -33K | +44% |
| Net profit | DKK -60K | +25% |
| Total assets | DKK 200K | -24% |
| Equity | DKK 168K | -26% |
| Employees | 12 | — |
Legal name
NP Bioinnovation A/S
CVR number
41598263
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
12. august 2020
Share capital
DKK 400.000
Employees
12 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør eller af 2 bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er at udvikle lægemidler og dermed beslægtet virksomhed.
Address
Vandtårnsvej 62A, 1. b
Email
info@nordicuspartners.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -14 | -8 | -94 | -59 | -32 |
| Staff expenses | -0 | -0 | -0 | -0 | -1 |
| EBITDA | -14 | -8 | -94 | -59 | -33 |
| Depreciation & amort. | -0 | -0 | -3 | -21 | -26 |
| EBIT | -14 | -8 | -97 | -80 | -59 |
| Net financials | -790 | 160 | 8 | 0 | -1 |
| Profit before tax | -805 | 152 | -89 | -80 | -60 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -805 | 152 | -89 | -80 | -60 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 139 | 66 | 362 | 263 | 200 |
| Equity | -765 | 37 | 308 | 228 | 168 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 903 | 29 | 54 | 35 | 32 |
| Total debt | 903 | 29 | 54 | 35 | 32 |
EBITDA margin
-3286400.0%
This company
15.8%
Market median
-20800100% vs market
20212025
Equity ratio
84.1%
This company
38.2%
Market median
+120% vs market
20212025
Return on equity
-35.8%
This company
18.4%
Market median
-295% vs market
20212025
Net profit margin
-6006900.0%
This company
8.1%
Market median
-74159359% vs market
20212025
Asset turnover
-0.16×
This company
1.12×
Market median
-114% vs market
20212025
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-08-12 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TG Management | Management | 2020 | — | — |
HM Management | Management | 2020 | — | — |
CT Management | Management | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2023 | |
GK PARTNERS ApS | Company | 66.7% | 66.7% | 2022 |
BIO-CONVERT A/S | Company | 5.0% | 5.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NP Bioinnovation A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tom Glæsner Larsen | Management | 0 companies |
| Hans Martin Dam | Management | 0 companies |
| Christian Torben Hill-Madsen | Management | 0 companies |
| Allan Traugott Wehnert | Board of Directors | 0 companies |
| Peter Severin Bach | Chairman | 0 companies |
| Henrik Rouf | Board of Directors | 0 companies |
| Henrik Keller | Board of Directors | 0 companies |